1 week Ago By Defense World Staff
Legal & General Group Plc boosted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO – Free Report) by 9.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC.
The institutional investor owned 23,471 shares of the company’s stock after acquiring an additional 1,983 shares during the period. Legal & General Group Plc owned 0.05% of Soleno Therapeutics worth $1,055,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC boosted its holdings in Soleno Therapeutics by 1,154.4% during the 4th quarter.
AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after acquiring an additional 658 shares during the last quarter. US Bancorp DE bought a new stake in Soleno Therapeutics in the 4th quarter valued at about $34,000. Avanza Fonder AB bought a new stake in Soleno Therapeutics in the 4th quarter valued at about $76,000.
Springhill Fund Asset Management HK Co Ltd bought a new stake in Soleno Therapeutics in the 4th quarter valued at about $81,000. Finally, Avior Wealth Management LLC bought a new stake in Soleno Therapeutics in the 4th quarter valued at about $89,000. Institutional investors own 97.
42% of the company’s stock. Insider Transactions at Soleno TherapeuticsIn other news, CEO Bhatnagar Anish sold 699,095 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.
62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares of the company’s stock, valued at $39,021,879.
12. This trade represents a 54.78 % decrease in their position.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Michael F. Huang sold 14,583 shares of the firm’s stock in a transaction that occurred on Thursday, March 27th.
The shares were sold at an average price of $69.51, for a total value of $1,013,664.33.
Following the completion of the sale, the vice president now directly owns 36,817 shares of the company’s stock, valued at $2,559,149.67. The trade was a 28.
37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 942,672 shares of company stock valued at $64,058,781 over the last 90 days.
Company insiders own 12.30% of the company’s stock. Soleno Therapeutics Stock Down 1.
3 %Shares of Soleno Therapeutics stock opened at $73.26 on Monday. The company has a market cap of $3.
66 billion, a price-to-earnings ratio of -22.07 and a beta of -2.29.
The company’s 50 day moving average is $57.41 and its 200 day moving average is $52.87.
Soleno Therapeutics, Inc. has a twelve month low of $36.93 and a twelve month high of $74.
50. Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($1.
27) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.41).
Sell-side analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.
Analyst Ratings ChangesSeveral brokerages have recently weighed in on SLNO. Robert W. Baird upped their price target on Soleno Therapeutics from $72.
00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, March 27th. Cantor Fitzgerald upped their price target on Soleno Therapeutics from $67.
00 to $123.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Laidlaw upped their price target on Soleno Therapeutics from $75.
00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and set a $100.
00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Finally, Stifel Nicolaus upped their price objective on shares of Soleno Therapeutics from $74.00 to $108.
00 and gave the stock a “buy” rating in a research report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Soleno Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $104.
67.Get Our Latest Research Report on Soleno TherapeuticsSoleno Therapeutics Company Profile (Free Report)Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Featured StoriesFive stocks we like better than Soleno Therapeutics3 Tickers Leading a Meme Stock RevivalTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryHow to Know Which Cryptocurrency to Buy: A Guide for InvestorsO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsWhat is a SEC Filing?Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2.
